Nita Limdi

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. ncbi Warfarin pharmacogenetics
    Nita A Limdi
    Department of Neurology, University of Alabama, Birmingham, Alabama 35294 0021, USA
    Pharmacotherapy 28:1084-97. 2008
  2. ncbi Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
    N A Limdi
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294 0021, USA
    Blood Cells Mol Dis 43:119-28. 2009
  3. ncbi Kidney function influences warfarin responsiveness and hemorrhagic complications
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham, 1719 6th Avenue South, CIRC 312, Birmingham, Alabama 35294 0021, USA
    J Am Soc Nephrol 20:912-21. 2009
  4. ncbi VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham, 1719 6th Avenue South, CIRC 312, Birmingham AL 35294 0021, USA
    Pharmacogenomics 9:1445-58. 2008
  5. ncbi Expectations, validity, and reality in pharmacogenetics
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294 0021, USA
    J Clin Epidemiol 63:960-9. 2010
  6. ncbi Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans
    Nita A Limdi
    University of Alabama at Birmingham, Department of Neurology, 1719 6th Avenue South, CIRC 312, Birmingham, AL 35294 0021, USA
    Pharmacogenomics 9:511-26. 2008
  7. ncbi Warfarin dosing in patients with impaired kidney function
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham, AL 35294 0021, USA
    Am J Kidney Dis 56:823-31. 2010
  8. ncbi Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin
    N A Limdi
    Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Clin Pharmacol Ther 83:312-21. 2008
  9. ncbi Safety of rapid intravenous loading of valproate
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham Epilepsy Center, Birmingham, AL 35294 0021, USA
    Epilepsia 48:478-83. 2007
  10. ncbi Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy
    N A Limdi
    Department of Neurology, University of Alabama at Birmingham, 1719 6th Avenue South, CIRC 312, 35294 0021, USA
    Blood Cells Mol Dis 37:100-6. 2006

Research Grants

  1. Pharmacogenetic Optimization of Anticoagulation Therapy
    Nita Limdi; Fiscal Year: 2007
  2. Genetic and Environmental Determinants of Warfarin Response
    Nita A Limdi; Fiscal Year: 2010
  3. Genetic and Environmental Determinants of Warfarin Response
    Nita Limdi; Fiscal Year: 2009
  4. Genetic and Environmental Determinants of Warfarin Response
    Nita Limdi; Fiscal Year: 2009

Detail Information

Publications16

  1. ncbi Warfarin pharmacogenetics
    Nita A Limdi
    Department of Neurology, University of Alabama, Birmingham, Alabama 35294 0021, USA
    Pharmacotherapy 28:1084-97. 2008
    ..However, the routine use of CYP2C9 and VKORC1 genotyping in the general patient population who begin warfarin therapy is not supported by evidence currently available...
  2. ncbi Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
    N A Limdi
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294 0021, USA
    Blood Cells Mol Dis 43:119-28. 2009
    ..Herein we present the influence of CYP2C9 and VKORC1 C1173T on warfarin response during the first 30 days of therapy...
  3. ncbi Kidney function influences warfarin responsiveness and hemorrhagic complications
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham, 1719 6th Avenue South, CIRC 312, Birmingham, Alabama 35294 0021, USA
    J Am Soc Nephrol 20:912-21. 2009
    ..Diminished renal function may have implications for a larger proportion of warfarin users than previously estimated...
  4. ncbi VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham, 1719 6th Avenue South, CIRC 312, Birmingham AL 35294 0021, USA
    Pharmacogenomics 9:1445-58. 2008
    ..However, the inadequate representation of African-Americans and the assessment of a few VKORC1 polymorphisms have hindered this effort...
  5. ncbi Expectations, validity, and reality in pharmacogenetics
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294 0021, USA
    J Clin Epidemiol 63:960-9. 2010
    ....
  6. ncbi Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans
    Nita A Limdi
    University of Alabama at Birmingham, Department of Neurology, 1719 6th Avenue South, CIRC 312, Birmingham, AL 35294 0021, USA
    Pharmacogenomics 9:511-26. 2008
    ....
  7. ncbi Warfarin dosing in patients with impaired kidney function
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham, AL 35294 0021, USA
    Am J Kidney Dis 56:823-31. 2010
    ..Unfortunately, few data exist to guide dose adjustment in patients with decreased kidney function. Here, we determine the degree of warfarin dose reduction associated with kidney impairment and make recommendations for warfarin dosing...
  8. ncbi Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin
    N A Limdi
    Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Clin Pharmacol Ther 83:312-21. 2008
    ..7; 95% CI: 0.7-4.4) or minor (HR 0.8; 95% CI: 0.5-1.3) hemorrhage. The variant CYP2C9 genotype is associated with an increased risk of major hemorrhage, which persists even after stabilization of therapy...
  9. ncbi Safety of rapid intravenous loading of valproate
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham Epilepsy Center, Birmingham, AL 35294 0021, USA
    Epilepsia 48:478-83. 2007
    ..The present study was designed to evaluate the safety of administration of undiluted VPA (20 or 30 mg/kg/min) administered intravenously at rates of 6 or 10 mg/kg/min...
  10. ncbi Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy
    N A Limdi
    Department of Neurology, University of Alabama at Birmingham, 1719 6th Avenue South, CIRC 312, 35294 0021, USA
    Blood Cells Mol Dis 37:100-6. 2006
    ..In European Americans, but not in African Americans, the GA genotype was more prevalent in patients with venous compared to arterial thromboembolic events...
  11. ncbi Efficacy of rapid IV administration of valproic acid for status epilepticus
    N A Limdi
    University of Alabama School of Medicine, Birmingham, AL, USA
    Neurology 64:353-5. 2005
    ..5 mg/kg). Analysis of demographic, clinical, and treatment information indicated an overall efficacy of 63.3% and favorable tolerance of rapid administration...
  12. ncbi Functional imaging: II. Prediction of epilepsy surgery outcome
    Robert C Knowlton
    UAB Epilepsy Center, Department of Neurology, University of Alabama at Birmingham, School of Medicine, Birmingham, AL 35294 0001, USA
    Ann Neurol 64:35-41. 2008
    ....
  13. ncbi Effect of epilepsy magnetic source imaging on intracranial electrode placement
    Robert C Knowlton
    Epilepsy Center, Department of Neurology, University of Alabama at Birmingham, School of Medicine, Birmingham, AL 35294 0001, USA
    Ann Neurol 65:716-23. 2009
    ....
  14. ncbi Preference-based quality-of-life measures for neocortical epilepsy surgery
    Robert C Knowlton
    Department of Neurology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294 0001, USA
    Epilepsia 52:1018-20. 2011
    ..Seizure freedom achieved with polytherapy medical management may be less desirable than that achieved with surgery and monotherapy...
  15. ncbi Functional imaging: I. Relative predictive value of intracranial electroencephalography
    Robert C Knowlton
    Department of Neurology, University of Alabama at Birmingham Epilepsy Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0001, USA
    Ann Neurol 64:25-34. 2008
    ....
  16. ncbi The safety of rapid valproic acid infusion
    N A Limdi
    University of Alabama Epilepsy Center, University of Alabama at Birmingham, USA
    Epilepsia 41:1342-5. 2000
    ..The safety of rapid infusion of valproic acid has not been established, and this study was designed to explore the effects of rapid infusion in patients with acute seizures...

Research Grants6

  1. Pharmacogenetic Optimization of Anticoagulation Therapy
    Nita Limdi; Fiscal Year: 2007
    ..With the award of the K23 grant, structured training, guidance of mentors, environment and institutional support provided by the University, I will develop the skills necessary for a productive career in pharmacogenetics research. ..
  2. Genetic and Environmental Determinants of Warfarin Response
    Nita A Limdi; Fiscal Year: 2010
    ..This knowledge will provide an evidence base for future pre-prescription genotyping for accurate warfarin dosing and facilitate its use in qualifying patients. ..
  3. Genetic and Environmental Determinants of Warfarin Response
    Nita Limdi; Fiscal Year: 2009
    ..This knowledge will provide an evidence base for future pre-prescription genotyping for accurate warfarin dosing and facilitate its use in qualifying patients. ..
  4. Genetic and Environmental Determinants of Warfarin Response
    Nita Limdi; Fiscal Year: 2009
    ..This knowledge will provide an evidence base for future pre-prescription genotyping for accurate warfarin dosing and facilitate its use in qualifying patients. ..